IDEXX Laboratories, Inc. (NASDAQ:IDXX) is Capital Counsel LLC NY’s Largest Position

Capital Counsel LLC NY cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 508,481 shares of the company’s stock after selling 7,984 shares during the quarter. IDEXX Laboratories makes up 16.1% of Capital Counsel LLC NY’s investment portfolio, making the stock its largest position. Capital Counsel LLC NY’s holdings in IDEXX Laboratories were worth $321,131,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of IDEXX Laboratories by 5.6% in the second quarter. BlackRock Inc. now owns 8,274,891 shares of the company’s stock worth $5,226,006,000 after acquiring an additional 437,365 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of IDEXX Laboratories by 2,972.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 116,755 shares of the company’s stock worth $57,129,000 after acquiring an additional 112,955 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of IDEXX Laboratories by 13.1% in the second quarter. Bank of New York Mellon Corp now owns 834,072 shares of the company’s stock worth $526,758,000 after acquiring an additional 96,356 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of IDEXX Laboratories by 7.4% in the first quarter. Franklin Resources Inc. now owns 1,220,880 shares of the company’s stock worth $597,387,000 after acquiring an additional 83,615 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its position in shares of IDEXX Laboratories by 42.7% in the first quarter. Allianz Asset Management GmbH now owns 252,304 shares of the company’s stock worth $123,454,000 after acquiring an additional 75,496 shares during the last quarter. Institutional investors and hedge funds own 84.70% of the company’s stock.

Shares of NASDAQ IDXX traded down $37.61 during trading on Monday, reaching $642.03. 7,268 shares of the stock were exchanged, compared to its average volume of 408,796. The business’s 50-day moving average price is $678.38 and its 200 day moving average price is $598.56. IDEXX Laboratories, Inc. has a twelve month low of $364.58 and a twelve month high of $706.95. The company has a quick ratio of 1.17, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $54.62 billion, a price-to-earnings ratio of 81.01, a price-to-earnings-growth ratio of 4.10 and a beta of 0.92.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Friday, July 30th. The company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.33. IDEXX Laboratories had a net margin of 23.89% and a return on equity of 115.28%. The business had revenue of $826.14 million for the quarter, compared to analysts’ expectations of $794.64 million. During the same period in the previous year, the company posted $1.72 earnings per share. The business’s revenue for the quarter was up 29.6% compared to the same quarter last year. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 8.35 earnings per share for the current fiscal year.

In related news, EVP Nimrata Hunt sold 538 shares of IDEXX Laboratories stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $703.00, for a total value of $378,214.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Kathy V. Turner sold 276 shares of IDEXX Laboratories stock in a transaction on Friday, August 27th. The stock was sold at an average price of $678.00, for a total transaction of $187,128.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,886 shares of company stock worth $18,646,894. Corporate insiders own 2.06% of the company’s stock.

A number of brokerages have weighed in on IDXX. Guggenheim cut shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday, July 12th. Credit Suisse Group lifted their price target on shares of IDEXX Laboratories from $735.00 to $770.00 and gave the company an “outperform” rating in a research report on Friday, August 13th. The Goldman Sachs Group lifted their price target on shares of IDEXX Laboratories from $550.00 to $610.00 and gave the company a “neutral” rating in a research report on Tuesday, August 3rd. Finally, Barclays lifted their price target on shares of IDEXX Laboratories from $616.00 to $750.00 and gave the company an “overweight” rating in a research report on Monday, August 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $643.80.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management.

Recommended Story: How do buyers and sellers choose a strike price?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.